The dataset is raw diatom counts (minimum 250 count size) from a sediment core taken from within high saltmarsh at the mouth of Dronning Marie Dal in south east Greenland (63.470N, -41.925W). The data was collected on 19/07/2014 during a research cruise to the area as part of the X_Centuries research project funded by the Danish Council for Independent Research 30 (FNU) (grant no. DFF-0602-02526B). The core was taken using a spade to dig a shallow pit from which a sediment section was extracted, wrapped in plastic and transported to the laboratory. Diatom samples were taken from the sediment core in the laboratory at 0.25 and 0.5 cm intervals using a scalpel. Sediment samples were prepared for diatom analysis using standard methods (Palmer and Abbott 1986). Counts were taken under a light microscope at 400x magnification. Only unbroken valves were counted. The taxonomy follows Van der Werff and Huls (1958-74), Hartley (1996) and Patrick and Reimer (1966, 1975). The core top elevation was surveyed in the field using a Sokkisha level to mean tide level, established via a pressure transducer that logged tidal variations at 15-min intervals at Timmiarmiut, 100 km to the South, during fieldwork. These tidal levels were related to tidal predictions at Tasiilaq, 300 km to the NE. This data was collected to reconstruct recent (last ~300 years) of relative sea-level changes from this area, in conjunction with the modern diatom training set also collected from this location.

The Myotonic Muscular Dystrophy (MMD) Treatments market is experiencing steady growth, projected to reach a market size of $2.5 Billion by 2025, with a Compound Annual Growth Rate (CAGR) of 5%. This growth is driven by several factors. Increasing prevalence of MMD, coupled with advancements in understanding the disease's underlying mechanisms, are fueling the development of novel therapies. The pipeline includes promising gene therapies and targeted medications aimed at addressing the core pathology of MMD, offering hope for improved patient outcomes. The market is segmented by treatment type (medications, rehabilitative therapies, devices, surgeries) and application (hospitals, specialty clinics, ambulatory surgery centers). While medications currently dominate the market share, the increasing adoption of innovative rehabilitative therapies and advanced devices is anticipated to drive substantial growth in these segments over the forecast period (2025-2033). North America and Europe currently hold the largest market share due to higher healthcare expenditure and robust research and development activities in these regions. However, emerging economies in Asia-Pacific are poised for significant expansion, driven by rising awareness and increasing healthcare infrastructure development. Regulatory approvals for new therapies and increasing patient advocacy are also key drivers for market expansion. Despite positive growth projections, the market faces certain restraints. High treatment costs associated with novel therapies, along with the complexity and length of clinical trials for new drug development, pose significant challenges. Furthermore, the relatively low prevalence of MMD compared to other neuromuscular diseases limits the overall market size. However, ongoing research efforts and collaborative initiatives between pharmaceutical companies, research institutions, and patient advocacy groups are working to overcome these barriers and accelerate the development of effective and affordable MMD treatments. The long-term outlook for the MMD treatment market remains optimistic, with continued advancements likely to significantly improve the quality of life for patients affected by this debilitating disease.

Objective: To assess the feasibility, safety, and efficacy of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) in patients with Duchenne muscular dystrophy (DMD).

Methods: The Halt Cardiomyopathy Progression (HOPE)-Duchenne trial is a phase I/II, randomized, controlled, open-label trial (NCT02485938). Patients with DMD >12 years old, with substantial myocardial fibrosis, were randomized (1:1) to usual care (control) or global intracoronary infusion of CAP-1002 (75 million cells). Participants were enrolled at 3 US medical centers between January and August 2016 and followed for 12 months. An independent Data and Safety Monitoring Board provided safety oversight. Cardiac function and structure were assessed by MRI, and analyzed by a blinded core laboratory. Skeletal muscle function was assessed by performance of the upper limb (PUL).

Results: Twenty-five eligible patients (mean age 17.8 years; 68% wheelchair-dependent) were randomized to CAP-1002 (n = 13) or contro...